This address was delivered by Elizabeth R. Seaquist, MD, President, Medicine & Science, of the American Diabetes Association (ADA) at the Association's 74th Scientific Sessions in San Francisco, CA, on 15 June 2014. Dr. Seaquist is a professor of medicine at the University of Minnesota in Minneapolis, where she holds the Pennock Family Chair in Diabetes Research. She has been an ADA volunteer since 1987 and has served on several national committees and chaired the Association's work-group on Hypoglycemia in Diabetes. At the local level, she served a 2-year term as cochair of the ADA EXPO in Minneapolis. Dr. Seaquist is a clinical investigator interested in the complications of diabetes. Her research focuses on the effect of diabetes on brain metabolism structure and function. She directs the University of Minnesota site for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) trials and has an active clinical practice. She was the 2009 recipient of the ADA's Distinguished Clinical Scientist Award. Dr. Seaquist holds a Bachelor of Arts degree from Vassar College in Poughkeepsie, NY, and a doctorate in medicine from the University of Minnesota. She is board certified in internal medicine and endocrinology, diabetes, and metabolism. The ADA and Diabetes Care thank Dr. Seaquist for her outstanding leadership and service to the Association.
Bibliographical noteFunding Information:
The author acknowledges the ongoing and substantial support of her husband, Mark Fiddler, and her colleagues at the University of Minnesota, as well as that of the staff of the ADA Scientific and Medical division, particularly Matt Petersen. Duality of Interest. E.R.S. has served as a consultant for Locemia, Sanofi, Merck, and Skyepharma. She has received research grants from Eli Lilly and Company. No other potential conflicts of interest relevant to this article were reported.
© 2015 by the American Diabetes Association.